Status:

COMPLETED

Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborating Sponsors:

CTI BioPharma

Conditions:

Chronic Lymphocytic Leukemia

Small Lymphocytic Lymphoma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Additional active agents are needed to further improve the treatment of patients with CLL/SLL. Increasing information exists regarding the activity of arsenic trioxide in other hematologic malignancie...

Detailed Description

Upon determination of eligibility, patients will receive: * Arsenic Trioxide

Eligibility Criteria

Inclusion

  • To be included in this study, you must meet the following criteria:
  • Histologically proven B-cell CLL/SLL.
  • Must have had a minimum of 1 and a maximum of 3 previous systemic regimens
  • Must have progressive CLL/SLL
  • Measurable or evaluable disease
  • ECOG performance status 0, 1, or 2
  • Age \> 18 years.
  • Patients with cytopenias caused by bone marrow involvement are eligible
  • All patients must give written informed consent prior to entering this study.

Exclusion

  • You cannot participate in this study if any of the following apply to you:
  • Unstable active infection on the basis of neutropenia
  • Previous severe opportunistic infections
  • Severe immune mediated anemia or thrombocytopenia
  • Serious underlying medical conditions
  • Brain metastases or meningeal involvement
  • History of other neoplasms
  • Significant underlying heart dysfunction
  • Women who are pregnant or
  • Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Key Trial Info

Start Date :

April 1 2004

Trial Type :

INTERVENTIONAL

End Date :

April 1 2006

Estimated Enrollment :

41 Patients enrolled

Trial Details

Trial ID

NCT00193518

Start Date

April 1 2004

End Date

April 1 2006

Last Update

May 3 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tennessee Oncology, PLLC

Nashville, Tennessee, United States, 37023